Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gihan, El Assal"'
Autor:
Hany M. Dabbous, Manal H. El-Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-
Externí odkaz:
https://doaj.org/article/2801616f9f1a4ec286b074ac78b065d0
Autor:
Hany M. Dabbous, Manal H. El‑Sayed, Gihan El Assal, Hesham Elghazaly, Fatma F. S. Ebeid, Ahmed F. Sherief, Maha Elgaafary, Ehab Fawzy, Sahar M. Hassany, Ahmed R. Riad, Mohamed A. TagelDin
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Externí odkaz:
https://doaj.org/article/4b565f65ac4a46f0bd15948e52f78885
Autor:
Fatma F S Ebeid, Manal H El-Sayed, Gihan El Assal, Ahmed R Riad, Sahar M Hassany, Hany Dabbous, Hesham Elghazaly, Mohamed Awad Tageldin, Maha Elgaafary, Ahmed F Sherief, Ehab Fawzy
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-1 (2021)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5309ec6bc940720e07324d7b73743dd0
https://pubmed.ncbi.nlm.nih.gov/33790308
https://pubmed.ncbi.nlm.nih.gov/33790308
Autor:
Manal H El-Sayed, Gihan El Assal, Hany Dabbous, Hesham Elghazaly, Ehab Fawzy, Maha Elgaafary, Fatma Fs Ebeid, Ahmed R Riad, Mohamed Awad Tageldin, Ahmed F Sherief, Sahar M Hassany
Background: Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases.Methods: A rando
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a3d34b2ebcd2069dbeb3450763873d9
https://doi.org/10.21203/rs.3.rs-83677/v1
https://doi.org/10.21203/rs.3.rs-83677/v1
Autor:
Hany M, Dabbous, Manal H, El-Sayed, Gihan, El Assal, Hesham, Elghazaly, Fatma F S, Ebeid, Ahmed F, Sherief, Maha, Elgaafary, Ehab, Fawzy, Sahar M, Hassany, Ahmed R, Riad, Mohamed A, TagelDin
Publikováno v:
Scientific reports. 11(1)
Favipiravir is considered a potential treatment for COVID-19 due its efficacy against different viral infections. We aimed to explore the safety and efficacy of favipiravir in treatment of COVID-19 mild and moderate cases. It was randomized-controlle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ade280940d6db04ee480c078e1562098
https://pubmed.ncbi.nlm.nih.gov/34537808
https://pubmed.ncbi.nlm.nih.gov/34537808